Spero Therapeutics Inc（SPRO）の財務SPROSpero Therapeutics Inc

Spero Therapeutics, Inc. (SPRO) generates its revenue primarily from Collaboration Revenue Related Party, which accounts for 100.0% of total sales, equivalent to $258.00K. Understanding this concentration is critical for investors evaluating how SPRO navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Spero Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2921.71%, while the net margin is -2791.86%. These profitability ratios, combined with a Return on Equity (ROE) of 35.12%, provide a clear picture of how effectively SPRO converts its operational activities into shareholder value.

In the context of the broader market, SPRO competes directly with industry leaders such as NMAD and XBIT. With a market capitalization of $70.46M, it holds a significant position in the sector. When comparing efficiency, SPRO's gross margin of 100.00% stands against NMAD's N/A and XBIT's N/A. Such benchmarking helps identify whether Spero Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Spero's financial performance shows significant volatility, with a gross margin consistently at 100% but a troubling net loss of $9.6 million in Q2 2026. The company has seen a drastic decline in revenue, with zero reported for the latest quarter, raising concerns about its operational viability.